Sareum Holdings PLC Notice of AGM (6260P)
November 21 2016 - 1:01AM
UK Regulatory
TIDMSAR
RNS Number : 6260P
Sareum Holdings PLC
21 November 2016
(AIM: SAR) 21 November 2016
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Notice of AGM
The Company announces that a notice has been sent to its
shareholders to convene its Annual General Meeting ("AGM") which is
to be held at 10.00 a.m. on 15 December 2016 at the offices of WH
Ireland Limited, 24 Martin Lane, London EC4R 0DR.
Further to the announcement of the Company's final results for
the year ended 30 June 2016 released on 2 November 2016, the
Company announces that the report and accounts have been posted to
those shareholders that requested hard copies.
In addition, an e mail has been sent to both shareholders that
have opted for electronic communication and beneficial owners of
shares with information rights informing them, inter alia, that the
report and accounts are now available on the Company's website.
The notice of AGM and the aforementioned e mail are also
available on the Company's website www.sareum.com.
For further information:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser and
Co-Broker)
Chris Fielding / Nick Prowting 020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce / William Lynne 020 3764 2341/2342
The Communications Portfolio
(Sareum Media enquiries)
Ariane Comstive
Ariane.comstive@communications-portfolio.co.uk 07785 922 354
Notes for editors:
Sareum is a drug discovery and development company delivering
targeted small molecule therapeutics, focusing on cancer and
autoimmune disease, for licensing to pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum operates an outsourced research model, working with
international collaborators and a world-wide network of research
providers. Its most advanced programme (Chk1) commenced clinical
trials in May 2016 and was licensed to NASDAQ-listed ProNAi
Therapeutics in September 2016.
SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug
discovery technology platform that has so far produced the
Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease
research programmes, which are in the IND-enabling preclinical and
lead optimisation stages respectively. SKIL(R) can also generate
drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the symbol SAR. For further
information, please visit www.sareum.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOAAKFDBOBDDCDD
(END) Dow Jones Newswires
November 21, 2016 02:01 ET (07:01 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024